FDA reviewing safety of GnRH agonists

FDA is reviewing the safety of gonadotropin-releasing hormone (GnRH) agonists after data from published studies showed

Read the full 161 word article

User Sign In

Article Purchase

This article may not be distributed to non-subscribers

PURCHASE THIS ARTICLE FOR LIMITED ONE-TIME DISTRIBUTION AND WEBSITE POSTING $995.00 USD

PURCHASE